Pharma IQ's Pharma Distribution Survey report

LONDON, June 20, 2011 /PRNewswire/ --


Pharma IQ has just published the results of an Industry-wide Pharmaceutical Distribution Survey, conducted recently among 3,000 pharmaceutical distribution specialist with over 83 % of those surveyed directly responsible for distribution at their respective companies.

The results showed that that almost 75% of respondents are satisfied with the current level of service they received from external partners and solution providers they worked with at the distribution stage, but despite this over 70% of respondents expressed their interest in investing or working with different organisations.

With regard to the extent to which they trust their logistics partners to deliver products quickly, safely and without damage, the study revealed that 37.5 % of pharma distribution professionals would rate their current level of trust at the eight-out-of-ten. Half of respondents suggested that 75 % of shipments were being distributed quickly, safely and with minimal loss of product integrity and only half of all deliveries had reached the desired quality standard.

The survey was created as a part of the pre-conference research for Pharmaceutical Distribution Forum, taking place 13 - 15 September, 2011 in Amsterdam.

The results helped to shape the agenda and final speaker line-up which features Paul Wolstencroft, Director, European Logistics from Eli Lilly explaining the methodology employed at Eli Lilly to facilitate the transition and Michael Grogan, Vice President, Global Trade and Logistics from Actavis leading a session on European Pharmaceutical Distribution: Developing a Robust Strategy - A Holistic Overview.

Other important topics expressed by survey respondents and will be discussed at the event include:

  • Successfully launching a centralised distribution model in Europe with insights and experiences from both Roland Vandebrouck, Distribution Network Director EMEA, AstraZeneca and Hubert Koevoets, Director Transaction Management, Celgene
  • Risk mitigation in a global supply chain to improve product integrity and security (Menno Vliestra, Global Supply Chain, Finance and HR, Roche)
  • Ensuring fast, smooth and cost effective distribution into new markets with regional case studies from Bjorn Einar Kippe, Head of Nordic Supply Chain, Sanofi Aventis (Nordics) and Frank Binder, Director International Logistics & Supply Chain, Celgene (Asia)
  • Securing the product and staying on top of serialisation with new updates from Grant Courtney, EFPIA representative and Global Serialisation Lead at GlaxoSmithKline

To access the full survey report or to find out more about Pharmaceutical Distribution 2011 please visit Pharmaceutical Distribution's website, email  [email protected] or call +44(0)20-7368-9421.

Media contact: Joanna, +44(0)20-7368-9421, [email protected]  - Please contact for more information or images.

Press are invited to attend this important industry forum, if you would like to a complimentary press pass please email Joanna Checinska ([email protected])


SOURCE Pharma IQ

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.